Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1 - Tabular View

Tracking Information

First Received Date ^ICMJE

April 5, 2002

Last Updated Date

October 23, 2007

Start Date ^ICMJE

September 2001

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

safety of selegiline
pharmacokinetic assessment

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00033072 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

Official Title ^ICMJE

Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

Brief Summary

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Detailed Description

To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.

Study Phase

Phase I

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Randomized, Single Blind, Placebo Control

Condition ^ICMJE

Amphetamine-Related Disorders

Intervention ^ICMJE

Drug: Selegiline

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Active, not recruiting

Enrollment ^ICMJE

Completion Date

October 2002

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
Be able to verbalize understanding of consent form; provide written informed consent

Exclusion Criteria:

Please contact site for more information

Gender

Both

Ages

18 Years to 45 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00033072

Responsible Party

Study ID Numbers ^ICMJE

NIDA-CTO-0004-1

Study Sponsor ^ICMJE

National Institute on Drug Abuse (NIDA)

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Thomas Newton, M.D.

University of California, Los Angeles

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

November 2003

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP